You are here

Biological Therapeutics

From patented antibodies to tumour associated cell surface markers. We have a diverse portfolio with the opportunity to licence agents in pre-clinical to Phase II clinical development.

We are seeking a partner experienced in the field of cell therapy development and in the Chinese regulatory environment to take this technology through to first in man trials in China.

Read more

Tumor endothelial markers (TEMs) that are highly expressed in human tumor vasculature compared with vasculature in normal tissue hold clear therapeutic potential.

Read more

Several antibodies were raised against MUC1 and are commercialised, to enable use of antibody technologies targeting cancer cells via MUC1 and drug development for cancer patients.

Read more

The integrin ɑvß6 is an exciting emerging target for both imaging and therapy across many common tumour types including pancreatic, breast, oesophagus, head and neck, skin, lung and ovarian.

Read more

Clinical Phase I CEA is a 180 kDa tumour-associated antigen expressed in the developing foetus and a wide variety of tumours, including those of the GI tract (e.g.

Read more

Pages